Abstract
Purpose
To develop a multi-parameter intrahepatic cholangiocarcinoma (ICC) scoring system and compare its diagnostic performance with contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system M (LR-M) criteria for differentiating ICC from hepatocellular carcinoma (HCC).
Methods
This retrospective study enrolled 62 high-risk patients with ICCs and 62 high-risk patients with matched HCCs between January 2022 and December 2022 from two institutions. The CEUS LR-M criteria was modified by adjusting the early wash-out onset (within 45 s) and the marked wash-out (within 3 min). Then, a multi-parameter ICC scoring system was established based on clinical features, B-mode ultrasound features, and modified LR-M criteria.
Result
We found that elevated CA 19-9 (OR=12.647), lesion boundary (OR=11.601), peripheral rim-like arterial phase hyperenhancement (OR=23.654), early wash-out onset (OR=7.211), and marked wash-out (OR=19.605) were positive predictors of ICC, whereas elevated alpha-fetoprotein (OR=0.078) was a negative predictor. Based on these findings, an ICC scoring system was established. Compared with the modified LR-M and LR-M criteria, the ICC scoring system showed the highest area under the curve (0.911 vs. 0.831 and 0.750, both p<0.05) and specificity (0.935 vs. 0.774 and 0.565, both p<0.05). Moreover, the numbers of HCCs categorized as LR-M decreased from 27 (43.5%) to 14 (22.6%) and 4 (6.5%) using the modified LR-M criteria and ICC scoring system, respectively.
Conclusion
The modified LR-M criteria-based multi-parameter ICC scoring system had the highest specificity for diagnosing ICC and reduced the number of HCC cases diagnosed as LR-M category.
Graphical abstract
Similar content being viewed by others
Abbreviations
- ICC:
-
Intrahepatic cholangiocarcinoma
- HCC:
-
Hepatocellular carcinoma
- CEUS:
-
Contrast-enhanced ultrasound
- BUS:
-
B-mode ultrasound
- LI-RADS:
-
Liver imaging reporting and data system
- APHE:
-
Arterial phase hyperenhancement
- AP:
-
Arterial phase
- PVP:
-
Portal venous phase
- LP:
-
Late phase
- rim APHE:
-
Rim-like hyperenhancement
- IRQ:
-
Interquartile range
- ROC:
-
Receiver operating characteristic
- HBV:
-
Hepatitis B virus
- HCV:
-
Hepatitis C virus
- AFP:
-
Alpha-fetoprotein
- OR:
-
Odds ratio
- CI:
-
Confidence interval
- AUC:
-
Area under the curve
References
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. (2021) Biliary tract cancer. Lancet, 397(10272):428-444. https://doi.org/10.1016/S0140-6736(21)00153-7
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68(6):394-424. https://doi.org/10.3322/caac.21492
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, Gores GJ. (2014) Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol, 60(6):1268-1289. https://doi.org/10.1016/j.jhep.2014.01.021
Xue TC, Zhang BH, Ye SL, Ren ZG. (2015) Differentially expressed gene profiles of intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and combined hepatocellular-cholangiocarcinoma by integrated microarray analysis. Tumour Biol, 36(8):5891-5899. https://doi.org/10.1007/s13277-015-3261-1
Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg, 149(6):565-574. https://doi.org/10.1001/jamasurg.2013.5137
Zhang H, Yang T, Wu M, Shen F. (2016) Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett, 379(2):198-205. https://doi:https://doi.org/10.1016/j.canlet.2015.09.008
Bruix J, Sherman M. (2005) Management of hepatocellular carcinoma. Hepatology, 42(5):1208-1236. https://doi.org/10.1002/hep.20933
Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, et al. (2013) Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver--update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med, 34(1):11-29. https://doi.org/10.1055/s-0032-1325499
Joo I, Lee JM, Yoon JH. (2018) Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology, 288(1):7-13. https://doi.org/10.1148/radiol.2018171187
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48(5):599-641. https://doi.org/10.1016/j.ejca.2011.12.021
Kono Y, Lyshchik A, Cosgrove D, Dietrich CF, Jang HJ, Kim TK, Piscaglia F, Willmann JK, Wilson SR, Santillan C, Kambadakone A, Mitchell D, Vezeridis A, Sirlin CB. (2017) Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS®): the official version by the American College of Radiology (ACR). Ultraschall Med, 38(1):85-86. https://doi.org/10.1055/s-0042-124369
Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, Fraquelli M, Riccardi L, De Bonis L, Sangiovanni A, Leoni S, Zocco MA, Rossi S, Alessi N, Wilson SR, Piscaglia F. (2018) Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol, 68(3):485-492. https://doi.org/10.1016/j.jhep.2017.11.007
Li F, Li Q, Liu Y, Han J, Zheng W, Huang Y, Zheng X, Cao L, Zhou JH. (2020) Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol, 30(1):461-470. https://doi.org/10.1007/s00330-019-06317-2
Jiang W, Zeng ZC, Tang ZY, Fan J, Sun HC, Zhou J, Zeng MS, Zhang BH, Ji Y, Chen YX. (2011) A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol, 22(7):1644-1652. https://doi.org/10.1093/annonc/mdq650
Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. (2014) Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg, 149:565–574. https://doi.org/10.1001/jamasurg.2013.5137
Zeng D, Xu M, Liang JY, Cheng MQ, Huang H, Pan JM, Huang Y, Tong WJ, Xie XY, Lu MD, Kuang M, Chen LD, Hu HT, Wang W. (2022) Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017. Radiol Med, 127 (1), 1-10. https://doi.org/10.1007/s11547-021-01417-w
Huang JY, Li JW, Ling WW, Li T, Luo Y, Liu JB, Lu Q. (2020) Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma? World J Gastroenterol, 26(27):3938-3951. https://doi.org/10.3748/wjg.v26.i27.3938
Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, Liu GJ, Wang Z, Lin MX, Lu MD. (2010) Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol, 20(3):743-753. https://doi.org/10.1007/s00330-009-1599-8
Chen LD, Ruan SM, Liang JY, Yang Z, Shen SL, Huang Y, Li W, Wang Z, Xie XY, Lu MD, Kuang M, Wang W. (2018) Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: a predictive model using contrast-enhanced ultrasound. World J Gastroenterol, 24(33):3786-3798. https://doi.org/10.3748/wjg.v24.i33.3786
Liu GJ, Wang W, Lu MD, Xie XY, Xu HX, Xu ZF, Chen LD, Wang Z, Liang JY, Huang Y, Li W, Liu JY. (2015) Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Liver Cancer, 4(4):241-252. https://doi.org/10.1159/000367738
Xu HX, Chen LD, Liu LN, Zhang YF, Guo LH, Liu C. (2012) Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol, 85(1016):1029-1037. https://doi.org/10.1259/bjr/21653786
Yuan MX, Li R, Zhang XH, Tang CL, Guo YL, Guo DY, Luo MK. (2016) Factors affecting the enhancement patterns of intrahepatic cholangiocarcinoma (ICC) on contrast-enhanced ultrasound (CEUS) and their pathological correlations in patients with a single lesion. Ultraschall Med, 37(6):609-618. https://doi.org/10.1055/s-0034-1399485
Han J, Liu Y, Han F, Li Q, Yan C, Zheng W, Wang J, Guo Z, Wang J, Li A, Zhou J. (2015) The degree of contrast washout on contrast-enhanced ultrasound in distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Ultrasound Med Biol, 41(12):3088-3095. https://doi.org/10.1016/j.ultrasmedbio.2015.08.001
Kong WT, Wang WP, Huang BJ, Ding H, Mao F. (2014) Value of wash-in and wash-out time in the diagnosis between hepatocellular carcinoma and other hepatic nodules with similar vascular pattern on contrast-enhanced ultrasound. J Gastroenterol Hepatol, 29(3):576-580. https://doi.org/10.1111/jgh.12394
Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, Guo DY, Yan XC. (2014) Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One, 9(5):e98612. https://doi.org/10.1371/journal.pone.0098612
Zheng W, Li Q, Zou XB, Wang JW, Han F, Li F, Huang LS, Li AH, Zhou JH. (2020) Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology, 294(2):299–307. https://doi.org/10.1148/radiol.2019190878
Chan KM, Tsai CY, Yeh CN, Yeh TS, Lee WC, Jan YY, Chen MF. (2018) Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol, 18(1):180. https://doi.org/10.1186/s12876-018-0912-x
Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klümpen HJ, et al. (2022) Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol, 76(5):1109-1121. https://doi.org/10.1016/j.jhep.2021.12.010
Chen VL, Sharma P. (2020) Role of biomarkers and biopsy in hepatocellular carcinoma. Clin Liver Dis, 24(4):577-590. https://doi.org/10.1016/j.cld.2020.07.001
Zheng Y, Zhu M, Li M. (2020) Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma. J Cancer Res Clin Oncol, 146(10):2439-2446. https://doi.org/10.1007/s00432-020-03331-6
American College of Radiology. CT/MRI LI-RADS v2018 core. Published 2018. Accessed February 5, 2022. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core
Acknowledgements
We would like to acknowledge the effort and support of all authors in the study.
Funding
This work was supported in part by the National Natural Science Foundation of China (Grant 82202174), the Science and Technology Commission of Shanghai Municipality (Grant 19DZ2251100), Shanghai Municipal Health Commission (Grant SHSLCZDZK03502), Shanghai Science and Technology Innovation Action Plan (21Y11911200), and Fundamental Research Funds for the Central Universities (ZD-11-202151), Scientific Research and Development Fund of Zhongshan Hospital of Fudan University (Grant 2022ZSQD07).
Author information
Authors and Affiliations
Consortia
Contributions
WLF, GX, SYT and ZCK: study design; WLF and ZBY: statistical analysis; SYK, LXL, YDH and LQ: data collection and data interpretation; WLF: writing of the first draft of the paper; ZCK and XHX: revision of the manuscript; YHH, LD, YX, HXY, XHS, WX and HH: providing administrative, technical and material support; XHX and ZCK: supervising the study.
Corresponding authors
Ethics declarations
Conflict of interest
These authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.
Ethical approval
Institutional Review Board approval was obtained (B2022-569R).
Informed consent
Informed consent from patients was waived for the retrospective nature of the study by the Institutional Review Board.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Wang, LF., Guan, X., Shen, YT. et al. A multi-parameter intrahepatic cholangiocarcinoma scoring system based on modified contrast-enhanced ultrasound LI-RADS M criteria for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Abdom Radiol 49, 458–470 (2024). https://doi.org/10.1007/s00261-023-04114-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-023-04114-6